Pneumocystis pneumonia in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Martin, S I ^a   Fishman, J A ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Pneumocystis; Pneumonia; Prophylaxis

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ATOVAQUONE; AZATHIOPRINE; BLEOMYCIN; CALCINEURIN INHIBITOR; CLADRIBINE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; CYTARABINE; DAPSONE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PREDNISONE; PRIMAQUINE; RAPAMYCIN; TACROLIMUS; TRIMETHOPRIM; TRIMETREXATE; UNINDEXED DRUG;

ADJUVANT THERAPY; BONE MARROW SUPPRESSION; BRONCHOSCOPY; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPNEA; ELECTROLYTE DISTURBANCE; EPIDEMIOLOGICAL DATA; FEVER; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOXEMIA; INCIDENCE; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LUNG BIOPSY; LUNG LAVAGE; LUNG TRANSPLANTATION; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; ORGAN TRANSPLANTATION; PANCREAS INSUFFICIENCY; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; SYMPTOM; THORAX PAIN; TREATMENT DURATION;

ANTIFUNGAL AGENTS; HUMANS; ORGAN TRANSPLANTATION; PNEUMONIA, PNEUMOCYSTIS;

EID: 72949097242     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02914.x     Document Type: Review

References (51)

1. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 17 : 770 782.
2. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: Evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978 61 : 35 41.
3. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001 286 : 2450 2460.
4. De Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: Interhuman transmission or a common environmental source? Clin Infect Dis 2007 44 : 1143 1149.
5. Schmoldt S, Schuhegger R, Wendler T et al. Molecular evidence of nosocomial Pneumocystis jiroveci transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008 46 : 966 971.
6. Hocker B, Wendt C, Nahimana A, Tonshoff B, Hauser PM. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005 11 : 330 332.
7. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998 42 : 995 1004.
8. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 71 : 5 13.
9. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995 49 : 135 142.
10. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993 17 (Suppl 2 S416 422.
11. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 357 : 2601 2614.
12. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006 43 : 16 24.
13. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997 175 : 901 904.
14. Hardy AM, Wajszczuk CP, Suffredini AF, Hakala TR, Ho M. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis 1984 149 : 143 147.
15. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996 62 : 421 423.
16. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000 343 : 225 226.
17. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001 33 : 1397 1405.
18. Munoz P, Munoz RM, Palomo J, Rodriguez-Creixems M, Munoz R, Bouza E. Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule. Medicine (Baltimore) 1997 76 : 415 422.
19. Arend SM, Westendorp RG, Kroon FP et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996 22 : 920 925.
20. Lyytikainen O, Ruutu T, Volin L et al. Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1996 17 : 1057 1059.
21. Masur H, Ognibene FP, Yarchoan R et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989 111 : 223 231.
22. Castagnola E, Dini G, Lanino E et al. Low CD4 lymphocyte count in a patient with P. carinii pneumonia after autologous bone marrow transplantation. Bone Marrow Transplant 1995 15 : 977 978.
23. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992 267 : 832 837.
24. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000 118 : 712 720.
25. Kovacs JA, Hiemenz JW, Macher AM et al. Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984 100 : 663 671.
26. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: Clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007 13 : 1 7.
27. Kovacs JA, Ng VL, Masur H et al. Diagnosis of Pneumocystis carinii pneumonia: Improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988 318 : 589 593.
28. LaRocque RC, Katz JT, Perruzzi P, Baden LR. The utility of sputum induction for diagnosis of Pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus. Clin Infect Dis 2003 37 : 1380 1383.
29. Thomas CF, Jr., Limper AH. Pneumocystis pneumonia: Clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin Respir Infect 1998 13 : 289 295.
30. Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med 1984 101 : 1 7.
31. Bondoc AY, White DA. Granulomatous Pneumocystis carinii pneumonia in patients with malignancy. Thorax 2002 57 : 435 437.
32. Studemeister A, Dass S. A patient with dyspnea, cough, and fever. Clin Infect Dis 2006 43 : 1461 1462, 1490 1461.
33. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Preemptive treatment of fungal infection based on plasma (1 -> 3)beta-D-glucan levels after liver transplantation. Infection 2007 35 : 346 351.
34. Kawagishi N, Miyagi S, Satoh K, Akamatsu Y, Sekiguchi S, Satomi S. Usefulness of beta-D glucan in diagnosing Pneumocystis carinii pneumonia and monitoring its treatment in a living-donor liver-transplant recipient. J Hepatobiliary Pancreat Surg 2007 14 : 308 311.
35. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996 3 : 197 199.
36. Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998 42 : 1309 1314.
37. Schmatz DM, Romancheck MA, Pittarelli LA et al. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci USA 1990 87 : 5950 5954.
38. Powles MA, Liberator P, Anderson J et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998 42 : 1985 1989.
39. Annaloro C, Della Volpe A, Usardi P, Lambertenghi Deliliers G. Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 2006 25 : 52 54.
40. Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation 2007 84 : 685 688.
41. Mandujano JF, D'Souza NB, Nelson S, Summer WR, Beckerman RC, Shellito JE. Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Crit Care Med 1995 151 : 1233 1238.
42. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996 156 : 177 188.
43. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: A review. Clin Infect Dis 1998 27 : 191 204.
44. Lee I, Barton TD, Goral S et al. Complications related to dapsone use for Pneumocystis jiroveci pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant 2005 5 : 2791 2795.
45. El-Sadr WM, Murphy RL, Yurik TM et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998 339 : 1889 1895.
46. Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004 38 : e76 e78.
47. Zavascki AP, Maia AL, Goldani LZ. Pneumocystis jiroveci thyroiditis: Report of 15 cases in the literature. Mycoses 2007 50 : 443 446.
48. Barber BA, Pegram PS, High KP. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1996 23 : 718 722.
49. Thomas CF Jr., Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007 5 : 298 308.
50. Bartlett MS, Vermund SH, Jacobs R et al. Detection of Pneumocystis carinii DNA in air samples: Likely environmental risk to susceptible persons. J Clin Microbiol 1997 35 : 2511 2513.
51. Olsson M, Lidman C, Latouche S et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998 36 : 1737 1740.